J B Chemicals & Pharmaceuticals Ltd
J B Chemicals & Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
1 of 2 strong
The short version
JB Chemicals aims for gradual recovery to previous growth trajectories post Q4 operational reset. JB Chemicals expects gradual normalization and recovery in growth starting Q1 FY27, post Q4 operational reset.
From J B Chemicals & Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- JB Chemicals aims for gradual recovery to previous growth trajectories post Q4 operational reset.
- India business expected to achieve double-digit (low to mid-teens) growth, likely taking a couple of quarters to normalize.
- International business anticipates single-digit growth starting Q2 FY27, factoring in geopolitical challenges.
- CDMO segment has strong growth drivers with multiple signed contracts but faces execution delays; growth momentum expected once execution improves.
- Growth strategies include increasing wallet share with existing top customers (Innova, Kenvue, P&G, Reckitt), expanding geographic footprint, and tapping new large customers globally.
- Merger synergies with Torrent Pharma expected to drive growth in branded business and improve margins.
2 more points management made on revenue & sales performance
Profitability & Margins
See what J B Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what J B Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- JB Chemicals and Pharma has several new contracts and projects signed in the CDMO segment with top global customers like Innova, Kenvue, P&G, and Reckitt.
- The company aims to accelerate execution and delivery of these signed contracts to convert them into revenue faster.
- Growth strategy includes increasing wallet share with existing customers by expanding geographic footprint, supplying existing products in additional markets.
2 more points management made on order book & pipeline
J B Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹904 Cr, net profit ₹101 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What J B Chemicals & Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were J B Chemicals & Pharmaceuticals Ltd Q4 FY26 results?
JB Chemicals aims for gradual recovery to previous growth trajectories post Q4 operational reset. JB Chemicals expects gradual normalization and recovery in growth starting Q1 FY27, post Q4 operational reset.
What is J B Chemicals & Pharmaceuticals Ltd share price analysis?
J B Chemicals & Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 53.8 with a market cap of ₹38,677 Cr. Investors should review the full earnings analysis for detailed insights.
Is J B Chemicals & Pharmaceuticals Ltd planning capital expenditure?
The provided transcript from JB Chemicals and Pharma's Q4 FY'26 earnings call does not explicitly mention any current or future capex, capital investments, or strategic investments.
Keep J B Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.